The European Commission has authorized XOLREMDI® (mavorixafor) as the first treatment for WHIM syndrome in the European Union.
The thread discusses Norgine's announcement of the European Commission's marketing authorization for XOLREMDI® (mavorixafor), the first treatment for WHIM syndrome in the EU. The posts highlight the approval process and the significance of …